Last reviewed · How we verify
Vaxigriptetra®
Vaxigriptetra is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus.
Vaxigriptetra is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus. Used for Seasonal influenza prevention in adults.
At a glance
| Generic name | Vaxigriptetra® |
|---|---|
| Also known as | Quadrivalent influenza vaccine (split-virion, inactivated) - QIV |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated antigens from two influenza A strains (H1N1 and H3N2) and two influenza B strains, which trigger both humoral and cellular immune responses. This provides protection against seasonal influenza infection by inducing neutralizing antibodies and T-cell responses against the included viral strains.
Approved indications
- Seasonal influenza prevention in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses (PHASE4)
- Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older (PHASE3)
- Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24
- Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23
- Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients (PHASE3)
- Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel (PHASE4)
- Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months
- Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |